Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials

Abstract

HP/TAZ lotion was associated with significant reductions in the severity of the clinical signs of psoriasis, with no safety concerns.

<p>Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults</p>

“…The primary efficacy endpoint was the percentage of subjects who achieved treatment success at week 8, with treatment success defined as at least a 2-point improvement in IGA score from baseline and achieving an IGA score of clear or almost clear (IGA 0/1). 25 ; (both p<.001)). 25 The results of these trials are summarized in Figure 1.…”

“…25 ; (both p<.001)). 25 The results of these trials are summarized in Figure 1. Safety evaluations in both studies were conducted through week 12.…”

Successful Management of a Black Male With Psoriasis and Dyspigmentation Treated With Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion: Case Report

“…The patient was enrolled in a phase 3, randomized, doubleblind, vehicle-controlled study that assessed HP/TAZ lotion in participants with moderate-to-severe psoriasis (NCT02462070); detailed methodology and study results have been previously published. 14,15 The patient, randomized to HP/TAZ for 8 weeks with a 4-week posttreatment follow-up, was instructed to apply a thin layer of HP/TAZ lotion once-daily over all affected areas.…”

“…10 Phase 3 clinical data have demonstrated efficacy and tolerability of HP/TAZ lotion in patients with moderate-to-severe localized plaque psoriasis. 14,15 Here, we present a case report of a Black male with moderate plaque psoriasis who was successfully treated with once-daily HP/TAZ lotion over 8 weeks, with resolution of skin dyspigmentation by week 12. Table 1).…”

A Novel Halobetasol Propionate 0.01%/Tazarotene 0.045% Fixed Combination Treatment for Psoriasis

“…Formulating halobetasol propionate at 0.01% and tazarotene at 0.045%—concentrations that fall below those standardly administered—may reduce potential irritant effects (Sugarman et al, ). Gold et al () previously noted that pruritis (2.2%), contact dermatitis (6.3%), and application site pain (2.6%) were the most frequently reported adverse events associated with HP/TAZ use (Gold et al, ). Furthermore, others found that HP/TAZ lotion showed no evidence of contact sensitization and was significantly less irritating than tazarotene cream, an often‐limiting characteristic of topical retinoids (Del Rosso, Kircik, Lin, & Pillai, ).…”